{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:27:13Z","timestamp":1790962033882,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejmech.2022.114907","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T02:28:21Z","timestamp":1667960901000},"page":"114907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"P1","title":["Identification of novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C inhibitors with anticancer effects"],"prefix":"10.1016","volume":"245","author":[{"given":"Zhendong","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert S.C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7868-8448","authenticated-orcid":false,"given":"Xiao-Feng","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114907_bib1","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114907_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tibs.2013.12.004","article-title":"KRAS: feeding pancreatic cancer proliferation","volume":"39","author":"Bryant","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2022.114907_bib3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114907_bib4","doi-asserted-by":"crossref","first-page":"14404","DOI":"10.1021\/acs.jmedchem.0c01312","article-title":"Small-molecule inhibitors directly targeting KRAS as anticancer therapeutics","volume":"63","author":"Chen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114907_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114907_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113816","article-title":"Targeting mutated GTPase KRAS in tumor therapies","volume":"226","author":"Fan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114907_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114907_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2008.06.020","article-title":"SnapShot: ras signaling","volume":"133","author":"Cully","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114907_bib9","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1126\/science.1062023","article-title":"The guanine nucleotide-binding switch in three dimensions","volume":"294","author":"Vetter","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114907_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.12.005","article-title":"Targeting KRAS mutated non-small cell lung cancer: a history of failures and a future of hope for a diverse entity","volume":"110","author":"Matikas","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2022.114907_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genone atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114907_bib12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"KRas (-G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114907_bib13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114907_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114907_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114907_bib16","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114907_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101974","article-title":"KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?","volume":"84","author":"Nagasaka","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2022.114907_bib18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","article-title":"Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state","volume":"6","author":"Patricelli","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2022.114907_bib19","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1021\/acsmedchemlett.9b00258","article-title":"Discovery of N-(1-acryloylazetidin-3-yl)-2-(1Hindol-1-yl) acetamides as covalent inhibitors of KRASG12C","volume":"10","author":"Shin","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114907_bib20","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1021\/acs.jmedchem.9b01720","article-title":"Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant GTPase KRASG12C","volume":"63","author":"Kettle","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114907_bib21","doi-asserted-by":"crossref","first-page":"15823","DOI":"10.1073\/pnas.1904529116","article-title":"Drugging an undruggable pocket on KRAS","volume":"116","author":"Kessler","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114907_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1021\/acsmedchemlett.1c00643","article-title":"A series of pyrazole analogs binding to KRASG12C as potential cancer treatment","volume":"13","author":"Rosse","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114907_bib23","doi-asserted-by":"crossref","first-page":"6940","DOI":"10.1021\/acs.jmedchem.2c00369","article-title":"Discovery of AZD4625, a covalent allosteric inhibitor of the mutant GTPase KRAS G12C","volume":"65","author":"Kettle","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114907_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113082","article-title":"Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS G12C inhibitors","volume":"213","author":"Xiao","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114907_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104825","article-title":"Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents","volume":"110","author":"Li","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114907_bib26","doi-asserted-by":"crossref","first-page":"14404","DOI":"10.1021\/acs.jmedchem.0c01312","article-title":"Small-molecule inhibitors directly targeting KRAS as anticancer therapeutics","volume":"63","author":"Chen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114907_bib27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2022.114907_bib28","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRAS G12C inhibition through a novel KRAS Switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2022.114907_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.apsb.2020.07.010","article-title":"Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2022.114907_bib30","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1073\/pnas.1116510109","article-title":"Small molecule ligands bind to a distinct pocket in Ras and inhibit SOS mediated nucleotide exchange activity","volume":"109","author":"Maurer","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114907_bib31","unstructured":"X. Wang, A.C. Burns, J.G. Christensen, J.M. Ketcham, J.D. Lawson, M.A. Marx, C.R. Smith, S. Allen, J.F. Blake, M.J. Chicarelli, J.R. Dahlke, D. Dai, J.B. Fell, J.P. Fischer, M.J. Mejia, B. Newhouse, P. Nguyen, J.M. O\u2019leary, S. Pajk, M.E. Rodriguez, P. Savechenkov, T.P. Tang, G.P.A. Vigers, Q. Zhao, Kras G12D Inhibitors, Patent WO\/2021041571, March 4, 2021."},{"key":"10.1016\/j.ejmech.2022.114907_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/anie.201104361","article-title":"A single phosphine ligand allows palladium-catalyzed intermolecular C-O bond formation with secondary and primary alcohols","volume":"50","author":"Wu","year":"2011","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.ejmech.2022.114907_bib33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.tcb.2020.07.003","article-title":"EMT, MET, plasticity, and tumor metastasis","volume":"30","author":"Bakir","year":"2020","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114907_bib34","series-title":"LLC the PyMOL Molecular Graphics System","author":"Schrodinger","year":"2015"},{"key":"10.1016\/j.ejmech.2022.114907_bib35","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1021\/acs.jmedchem.1c02058","article-title":"Discovery and structural optimization of toddacoumalone derivatives as novel PDE4 inhibitors for the topical treatment of psoriasis","volume":"65","author":"Song","year":"2022","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422008091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422008091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:47:13Z","timestamp":1759330033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422008091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":35,"alternative-id":["S0223523422008091"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114907","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C inhibitors with anticancer effects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114907"}}